Health-care companies fell as traders rotated out of high-risk biotech stocks.
Revolution Medicines shares rose after the biotech firm received commercial approval from the Food and Drug Administration for a pancreatic cancer pill touted by former Nebraska Sen. Ben Sasse as a "miracle drug" during his treatment.
A cyberattack at medical-device maker Boston Scientific triggered a global outage of key operational technology, leaving the company unable to fill orders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.